CN114870892B - 一种手性联萘催化剂及其制备方法和应用 - Google Patents

一种手性联萘催化剂及其制备方法和应用 Download PDF

Info

Publication number
CN114870892B
CN114870892B CN202210116253.XA CN202210116253A CN114870892B CN 114870892 B CN114870892 B CN 114870892B CN 202210116253 A CN202210116253 A CN 202210116253A CN 114870892 B CN114870892 B CN 114870892B
Authority
CN
China
Prior art keywords
catalyst
reaction
chiral
room temperature
stirring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210116253.XA
Other languages
English (en)
Other versions
CN114870892A (zh
Inventor
陈志敏
罗会云
丁同梅
朱登
杨钦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Jiaotong University
Original Assignee
Shanghai Jiaotong University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Jiaotong University filed Critical Shanghai Jiaotong University
Priority to CN202210116253.XA priority Critical patent/CN114870892B/zh
Publication of CN114870892A publication Critical patent/CN114870892A/zh
Application granted granted Critical
Publication of CN114870892B publication Critical patent/CN114870892B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/0272Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing elements other than those covered by B01J31/0201 - B01J31/0255
    • B01J31/0275Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing elements other than those covered by B01J31/0201 - B01J31/0255 also containing elements or functional groups covered by B01J31/0201 - B01J31/0269
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C319/00Preparation of thiols, sulfides, hydropolysulfides or polysulfides
    • C07C319/14Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/584Recycling of catalysts

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明涉及一种手性联萘催化剂及其制备方法和应用,制备方法是将三乙胺与三氯化磷,在二异丙胺、手性联萘酚衍生物和硒粉的共同作用下,生成轴手性联萘催化剂。与现有催化剂催化某些有机小分子反应的催化活性相比,本发明涉及3,3′‑二取代联萘衍生硒化物较未有3,3′‑二取代联萘催化剂具有更高的催化活性。

Description

一种手性联萘催化剂及其制备方法和应用
技术领域
本发明属于有机化学合成技术领域,具体涉及一种手性联萘催化剂及其制备方法和应用。
背景技术
联萘骨架分子广泛存在于具有生物活性的天然产物和药物中,也是现有手性催化剂和配体的重要组成部分。鉴于这种骨架的重要性,廉价、便捷的合成方法的开发是非常有必要的,为进一步丰富催化剂类型提供了更多选择。
联萘酚骨架(BINOL)是最著名的轴向手性分子代表之一,于1873年首次作为外消旋体制备,后来作为光学活性化合物制备(Tetrahedron 1985,41,3313.),其绝对构型于1971年确定(Tetrahedron Lett.1971,4617)。1979年,Noyori证明了BINOL是一种极好的手性配体,可以通过化学计量的氢化铝锂还原酮,生成99%ee的相应醇。(J.Am.Chem.Soc.1979,101,3129;J.Am.Chem.Soc.1979,101,5843.)双芳基轴向手性组分,特别是轴向手性联萘骨架分子,广泛应用于现有的有机领域不对称转化反应。已报道的联萘骨架的各种衍生物在催化有机合成应用主要依赖于联萘磷酸类衍生物。然而,关于手性联萘催化剂的制备仍存在许多不足,反应条件苛刻,原料不环保,且重复性差。
发明内容
本发明的目的就是为了克服上述现有技术存在的缺陷而提供一种反应条件温和,所使用原料便宜易制且基本无毒,可重复性好,底物适用范围广,经济性好的3,3′-二取代联萘衍生硒化物的合成方法及其应用。
本发明的目的可以通过以下技术方案来实现:
一种手性联萘催化剂,该催化剂为3,3′-二取代联萘衍生硒化物,包括以下结构式之一:
Figure BDA0003496408150000021
其中,R选自取代烷基、氟、苯基或者含氧杂原子基团。
优选地,所述的3,3′-二取代联萘衍生硒化物,包括以下结构式之一:
Figure BDA0003496408150000022
一种手性联萘催化剂的制备方法,将手性联萘酚与三氯化磷、三乙胺、二异丙胺,在硒粉以及溶剂的共同作用下,生成手性联萘催化剂,具体步骤为:将三氯化磷溶解于溶剂中,冷却至低温0℃后,并向其中加入三乙胺,反应后将体系升至室温,并添加二异丙胺,然后搅拌,在室温下向体系中加入手性联萘酚的衍生物搅拌反应,室温条件下加入硒,继续搅拌反应,后经减压蒸馏、柱色谱提纯,得到催化剂。
进一步地,所述溶剂为二氯甲烷。
进一步地,将三氯化磷溶解于二氯甲烷中,冷却至低温0℃后,并向其中逐滴滴加三乙胺,反应10min后将体系升至室温,并添加二异丙胺,然后搅拌2h,在室温下向体系中加入手性联萘酚的衍生物搅拌反应12h,室温条件下加入硒,继续搅拌反应2h。
一种手性联萘催化剂的应用,所述催化剂用于制备轴手性含硫双芳基衍生物,具体方法为:室温下,将双芳基苯酚、硫芳基试剂、催化剂和酸加入反应管中,低温条件下,加入溶剂,于氩气氛围中反应一段时间后,将体系升至一定温度,继续反应一段时间,后经减压蒸馏、柱色谱提纯,制得轴手性含硫双芳基衍生物;
该方法的合成路线为:
Figure BDA0003496408150000031
,其中,R选自选自烷基、氧烷基、卤素取代基,包含多取代或萘基骨架氧烷基、卤素取代基、硝基或氰基。
本发明催化剂所应用的方法的设计思路是以易制的双芳基苯酚和硫芳基试剂为原料,在催化剂和对氯苯磺酸的作用下,于低温下,氩气氛围中进行反应一段时间后,将体系升至一定温度,继续反应一段时间,制得轴手性含硫双芳基衍生物。
进一步地,所述的酸为对氯苯磺酸,所述的溶剂包括氘氯或氘氯与氘代二氯甲烷中的一种。
进一步地,所述的双芳基苯酚与硫芳基试剂的摩尔比为1:1.0-1.8,所述催化剂与双芳基苯酚的摩尔比为0.05-0.12:1。
进一步地,所述的酸与双芳基苯酚的摩尔比为0.05-0.12:1,所述的低温反应的温度为-60℃,反应时间为20-28h,升温后的反应的温度为-20℃,反应时间为4-7h。
与现有技术相比,本发明具有以下特点:
1)本发明方法通过对联萘酚底物3,3′位的官能团化,首次实现了手性3,3′-二取代联萘衍生硒化物催化剂合成。
2)本发明方法采用廉价易制的联萘酚类底物,反应过程避免了复杂的合成的路线。
3)本发明方法底物具有多样性,可以合成多种不同取代基的联萘衍生硒化物。
具体实施方式
下面通过实施例对本发明做进一步阐述,其目的仅在于更好理解本发明的内容。因此,本专利的保护范围并不限于这些实施例。
本实施方式中,化合物的氢核磁共振谱(1H NMR、13C NMR和19F NMR)由BrukerAVANCE III HD 400测定,溶剂为氘代氯仿,氘代甲醇,氘代二甲基亚砜,氘代二氯甲烷。化学位移(δ)以ppm为单位引用,以四甲基硅烷作为内标,多重性如下所示:s=单重态,d=双重态,t=三重态,q=四重态,m=多重态。高分辨率质谱分析(HRMS)数据是通过ESI技术和傅里叶变换离子回旋加速器(SolariX7.0T)的Q-TOF质谱测得。采用Daicel Chiralpak IE、Daicel Chiralpak IA、Daicel Chiralpak IC、Daicel Chiralpak IF、Chiralcel OD-H通过高效液相色谱(HPLC)分析测定产品的对映体过量(ee)。
本发明所制备的催化剂包括:
Figure BDA0003496408150000041
实施例1:化合物(R)-1c的制备
Figure BDA0003496408150000051
将1.4mmol三氯化磷溶解于超干DCM(6mL)中。将反应冷却至0℃,并向其中逐滴滴加7.0mmol Et3N。10min后,将反应体系升至室温,并添加1.4mmol二异丙胺,然后搅拌5h。在室温下向体系中加入1.4mmol 1c-0搅拌反应12h后,室温条件下加入硒,搅拌反应2小时。反应完成后用硅藻土过滤,并在真空中浓缩、旋干。粗产物通过硅胶(20:1 EtOAc:石油醚)纯化,得到白色固体化合物1c收率为45%。1H NMR(400MHz,Chloroform-d)δ8.09(d,J=16.9Hz,2H),7.97(m,2H),7.93–7.85(m,2H),7.81–7.71(m,2H),7.57–7.33(m,9H),7.34–7.16(m,3H),3.48(dp,J=20.6,6.8Hz,2H),0.91(d,J=6.7Hz,6H),0.52(d,J=6.8Hz,6H);13C NMR(101MHz,Chloroform-d)δ146.86,146.68,144.69,144.61,138.08,137.05,135.74,135.71,133.28,133.26,132.52,132.50,131.90,131.88,131.36,131.35,131.21,131.01,130.83,130.81,130.21,128.71,128.57,128.47,128.04,127.82,127.54,127.27,126.54,126.37,125.96,125.80,123.96,123.92,123.47,123.44,48.77,48.71,22.18,21.92,21.90;HRMS(ESI)m/z calcd.for C38H34NNaO2PSe(M+Na)+:670.1385,found:670.1377.[α]D 20=-280.8(c=1.0,CHCl3).
实施例2:化合物(R)-1d的制备
Figure BDA0003496408150000061
将1.05mmol三氯化磷溶解于超干DCM(5mL)中。将反应冷却至0℃,并向其中逐滴滴加5.25mmol Et3N。10min后,将反应体系升至室温,并添加1.05mmol二异丙胺,然后搅拌5h。在室温下向体系中加入1.05mmol 1d-0搅拌反应12h后,室温条件下加入硒,搅拌反应2小时。反应完成后用硅藻土过滤,并在真空中浓缩、旋干。粗产物通过硅胶(30:1EtOAc:石油醚)纯化,得到白色固体化合物1d收率为55%。1H NMR(400MHz,Chloroform-d)δ7.79(t,J=8.1Hz,2H),7.72(d,J=9.7Hz,1H),7.64(d,J=10.1Hz,1H),7.41(td,J=8.4,7.7,3.2Hz,2H),7.23–7.08(m,4H),3.85(dp,J=20.6,6.8Hz,2H),1.33(d,J=6.8Hz,6H),0.90(d,J=6.8Hz,6H);13C NMR(101MHz,CDCl3)δ153.46,153.43,152.86,152.83,150.95,150.92,150.37,150.34,137.87,137.70,137.54,135.47,135.38,135.30,135.22,130.94,130.92,130.85,130.09,130.01,128.06,127.95,127.11,127.05,126.92,126.87,126.14,125.87,125.80,125.12,125.10,124.97,124.94,124.08,123.45,113.55,113.54,113.37,112.96,112.78,47.89,47.83,30.56,29.63,29.33,28.83,21.51,21.49,21.47,20.59;19F NMR(376MHz,CDCl3)δ-128.11,-129.34.
实施例3:化合物(R)-1e的制备
Figure BDA0003496408150000062
将2.2mmol三氯化磷溶解于超干DCM(9mL)中。将体系冷却至0℃,并向其中逐滴添加11.0mmol Et3N。10min后,将反应体系缓慢至室温,并加入2.2mmol二异丙胺,然后搅拌反应5h。在室温下再加入2.2mmol 1e-0搅拌反应12h后,向体系中加入6.6mmol硒,搅拌反应2h。反应用硅藻土过滤,并在真空中浓缩旋干。粗产物通过硅胶(50:1EtOAc:石油醚)纯化,得到白色固体化合物1e,产率为61%。1H NMR(400MHz,Chloroform-d)δ7.92–7.69(m,4H),7.40(q,J=7.4,6.9Hz,2H),7.26–7.02(m,4H),4.04–3.73(m,2H),2.80(s,3H),2.62(s,3H),1.39(d,J=6.7Hz,6H),0.95(d,J=6.8Hz,6H);13C NMR(101MHz,Chloroform-d)δ148.24,148.07,146.26,146.18,131.93,131.92,131.73,131.71,131.69,131.67,131.14,131.13,130.65,130.62,130.05,130.04,129.19,129.16,127.72,127.50,127.14,127.08,125.63,125.53,125.49,125.46,122.64,122.62,122.24,122.21,48.93,48.87,22.73,22.71,22.35,18.91,17.62;HRMS(ESI)m/z calcd.for C28H30NNaO2PSe(M+Na)+:546.1072,found:546.1071.[α]D 20=-389.2(c=1.0,CHCl3).
实施例4:化合物(R)-1f的制备
Figure BDA0003496408150000071
将4.3mmol三氯化磷溶解于超干DCM(18mL)中。将体系溶液冷却至0℃,并向其中逐滴加入21.7mmol Et3N。10min后,将反应混合物缓慢升至室温,并向其中加入4.3mmol二异丙胺,然后搅拌反应5h。在室温下再加入4.3mmol 1f-0搅拌反应12h后,向体系中加入12.9mmol硒粉,搅拌反应2h。反应完成后用硅藻土过滤,并在真空中浓缩旋干。粗产物在硅胶(30:1EtOAc:石油醚)上纯化,得到白色固体的化合物1f,产率为58%。Mp:274.6~275.1℃.1H NMR(400MHz,Chloroform-d)δ7.81(t,J=7.7Hz,2H),7.48–7.36(m,3H),7.32–7.23(m,2H),7.20–7.02(m,3H),4.10(s,3H),4.00(s,3H),3.91(dp,J=20.5,6.8Hz,2H),1.41(d,J=6.7Hz,6H),0.91(d,J=6.8Hz,6H);13C NMR(101MHz,Chloroform-d)δ151.21,151.18,150.22,150.19,140.47,140.31,138.46,138.37,132.52,132.50,131.67,131.66,127.41,127.39,127.35,127.33,127.26,127.17,127.12,127.02,126.02,125.99,124.29,124.26,124.15,123.99,123.83,123.79,109.01,109.00,107.76,107.75,56.43,55.54,48.40,48.35,22.53,22.51,21.45;HRMS(ESI)m/z calcd.for C28H30NNaO4PSe(M+Na)+:578.0970,found:578.0969.[α]D 20=-408.8(c=1.0,CHCl3).
实施例5:化合物(R)-1g的制备
Figure BDA0003496408150000081
将1.3mmol三氯化磷溶解于超干DCM(5.5mL)中。将体系溶液冷却至0℃,并向其中逐滴滴加6.7mmol Et3N。10min后,将反应体系缓慢升至室温,并向体系中加入1.3mmol二异丙胺,然后搅拌反应5h后,向体系中加入1.3mmol 1g-0继续反应12h。在室温下加入4.0mmol硒粉,搅拌反应2h。反应完成后用硅藻土过滤,并在真空中浓缩旋干。粗产物通过硅胶(30:1EtOAc:石油醚)纯化,得到白色固体化合物1g,产率为59%。1H NMR(400MHz,Chloroform-d)δ7.78(t,J=7.8Hz,1H),7.47–7.33(m,2H),7.26(d,J=8.7Hz,0H),7.18–6.95(m,2H),4.52–4.12(m,2H),3.89(dp,J=20.5,6.7Hz,1H),1.56(dt,J=13.8,7.0Hz,3H),1.44(d,J=6.7Hz,3H),0.94(d,J=6.7Hz,3H);13C NMR(101MHz,Chloroform-d)δ150.54,150.51,149.69,149.66,140.70,140.54,138.69,138.60,132.59,132.58,131.71,131.69,127.42,127.39,127.37,127.23,127.12,126.97,125.92,125.89,124.36,124.33,124.07,123.87,123.83,109.68,109.66,108.91,108.90,77.36,64.87,64.49,48.18,48.12,22.88,22.85,21.14,14.97,14.82;HRMS(ESI)m/z calcd.for C30H34NNaO4PSe(M+Na)+:606.1283,found:606.1277.[α]D 20=-373.4(c=1.0,CHCl3).
实施例6:化合物(R)-1h的制备
Figure BDA0003496408150000091
将1.0mmol三氯化磷溶解于超干DCM(4.0mL)中。将体系溶液冷却至0℃,并向其中逐滴滴加4.8mmol Et3N。10min后,将反应体系缓慢升至室温,并加入1.0mmol二异丙胺,然后搅拌反应5h。在室温下再加入1.0mmol 1h-0搅拌反应12h。最后加入2.9mmol硒粉搅拌反应2h。反应完成后用硅藻土过滤,并在真空中浓缩。粗产物利用硅胶(30:1EtOAc:石油醚)纯化,得到白色固体化合物1h,产率为50%。1H NMR(400MHz,Chloroform-d)δ7.90–7.70(m,4H),7.60–7.51(m,2H),7.50–7.27(m,11H),7.21–7.03(m,3H),5.63–5.13(m,4H),3.83(ddq,J=20.5,13.4,6.7,6.0Hz,2H),1.33(d,J=6.8Hz,6H),0.86(d,J=6.7Hz,6H);13CNMR(101MHz,Chloroform-d)δ150.13,150.10,149.27,149.24,141.03,140.86,138.65,138.57,136.81,136.17,132.38,132.36,131.47,128.62,128.32,128.11,127.74,127.60,127.54,127.52,127.47,127.25,127.15,127.11,127.03,125.97,125.89,124.46,124.42,124.30,124.05,123.83,123.80,110.20,110.05,70.97,70.78,48.31,48.26,29.72,22.63,22.61,21.25;HRMS(ESI)m/z calcd.for C40H38NNaO4PSe(M+Na)+:730.1596,found:730.1592.[α]D 20=-260.4(c=1.0,CHCl3).
实施例7:化合物(R)-1i的制备
Figure BDA0003496408150000092
将1.2mmol三氯化磷溶解于超干DCM(5mL)中。将体系冷却至0℃,并向其中逐滴滴加5.8mmol Et3N。10min后,将反应体系缓慢升至室温,并向其中加入1.2mmol二仲丁胺,然后搅拌反应5h。室温下再加入1.2mmol 1e-0反应12h。最后室温下加入3.5mmol硒粉,搅拌2h。反应完成后用硅藻土过滤,并在真空中浓缩。粗产物在硅胶(20:1EtOAc:石油醚)上纯化,得到白色固体化合物1i,产率为45%。1H NMR(400MHz,Chloroform-d)δ7.80(dd,J=8.2,5.7Hz,2H),7.53–7.33(m,3H),7.30(s,1H),7.26(s,1H),7.17–6.99(m,3H),4.09(s,3H),4.00(m,3H),3.52(d,J=20.3Hz,2H),2.44–1.92(m,1H),1.90–1.55(m,2H),1.53–1.15(m,6H),0.87(m,5H),0.68(m,2H);13C NMR(101MHz,Chloroform-d)δ151.28,151.25,151.22,150.29,150.26,140.76,140.65,140.56,140.48,140.39,138.57,138.48,138.38,132.55,131.67,127.46,127.44,127.42,127.29,127.23,127.19,127.16,127.13,127.00,126.02,125.98,125.91,124.32,124.29,124.16,124.00,123.76,123.72,109.04,107.88,107.82,56.67,56.47,56.45,55.64,55.58,55.54,55.15,55.05,55.00,54.94,29.83,29.58,28.98,28.80,19.38,19.15,18.32,18.15,12.19,12.12,11.87,11.80;HRMS(ESI)m/z calcd.for C30H34NNaO4PSe(M+Na)+:606.1283,found:606.1283.[α]D 20=-346.2(c=1.0,CHCl3).
实施例8:化合物(R)-1j的制备
Figure BDA0003496408150000101
将4.0mmol三氯化磷溶解于超干DCM(16.0mL)中。将体系溶液冷却至0℃,并向其中逐滴滴加20.0mmol Et3N。10分钟后,将反应体系缓慢升至室温,并加入4.0mmol二仲丁胺,继续搅拌反应5小时。在室温条件下再加入4.0mmol 1g-0搅拌反应12h,然后加入12.0mmol硒粉,搅拌反应2h。反应完成后用硅藻土过滤,并在真空下浓缩。粗产物通过硅胶(50:1EtOAc:石油醚)纯化,得到白色固体化合物1j,产率为81%。1H NMR(400MHz,Chloroform-d)δ7.85–7.70(m,2H),7.50–7.34(m,3H),7.30(d,J=4.8Hz,1H),7.24(d,J=8.7Hz,1H),7.17–7.01(m,3H),4.45–4.05(m,4H),3.47(dq,J=21.5,6.9Hz,2H),2.31–1.99(m,1H),1.81–1.61(m,1H),1.60–1.50(m,6H),1.48–1.23(m,5H),1.07–0.83(m,6H),0.66(dt,J=23.2,7.4Hz,3H);13C NMR(101MHz,Chloroform-d)δ150.62,149.74,149.71,141.09,141.03,138.83,138.75,132.58,131.64,131.63,127.43,127.41,127.27,127.25,127.15,126.93,125.88,125.84,124.33,124.05,123.84,123.60,123.57,109.63,109.46,109.09,108.89,64.86,64.80,64.59,64.49,55.00,29.68,29.56,28.70,28.36,19.60,19.38,18.69,18.40,15.00,14.85,14.82,12.17,12.14,11.80,11.75;HRMS(ESI)m/z calcd.forC32H38NNaO4PSe(M+Na)+:634.1596,found:634.1587.[α]D 20=-380.6(c=1.0,CHCl3).
实施例9:化合物(R)-1k的制备
Figure BDA0003496408150000111
将1.6mmol三氯化磷溶解于超干DCM(6mL)中。将体系溶液冷却至0℃,并向其中逐滴加入7.9mmol Et3N。10min后,将反应混合物缓慢升至室温,并向其中加入1.6mmol二异丙胺,然后搅拌反应5h。在室温下再加入1.6mmol 1l-0搅拌反应12h后,向体系中加入4.7mmol硒粉,搅拌反应2h。反应完成后用硅藻土过滤,并在真空中浓缩旋干。粗产物在硅胶(100:1EtOAc:石油醚)上纯化,得到白色固体的化合物1l产率为48%。1H NMR(400MHz,Chloroform-d)δ7.96(d,J=8.8Hz,1H),7.91(d,J=8.2Hz,1H),7.83(d,J=8.2Hz,1H),7.50–7.34(m,5H),7.31–7.26(m,1H),7.16(d,J=8.4Hz,1H),7.10(m,1H),4.11(s,3H),3.89(dp,J=20.5,6.8Hz,2H),1.40(d,J=6.7Hz,6H),0.91(d,J=6.8Hz,6H);13C NMR(101MHz,CDCl3)δ151.26,151.23,148.46,148.30,138.41,138.32,132.70,132.69,132.60,132.59,131.37,131.35,130.38,130.36,128.38,127.43,127.41,127.33,127.27,127.11,126.65,126.13,125.57,124.50,124.46,124.09,122.50,122.47,121.39,121.37,109.03,109.01,56.46,48.24,48.19,22.60,22.58,21.49.
实施例10:化合物(R)-1l的制备
Figure BDA0003496408150000121
将4.4mmol三氯化磷溶解于超干DCM(18mL)中。将体系溶液冷却至0℃,并向其中逐滴加入21.9mmol Et3N。10min后,将反应混合物缓慢升至室温,并向其中加入4.4mmol二异丙胺,然后搅拌反应5h。在室温下再加入4.4mmol 1l-0搅拌反应12h后,向体系中加入13.1mmol硒粉,搅拌反应2h。反应完成后用硅藻土过滤,并在真空中浓缩旋干。粗产物在硅胶(30:1EtOAc:石油醚)上纯化,得到白色固体的化合物1l产率为94%。1H NMR(400MHz,Chloroform-d)δ7.78(t,J=8.4Hz,2H),7.50–7.33(m,3H),7.30–7.20(m,2H),7.08(m,3H),3.90(dp,J=20.6,6.8Hz,2H),1.39(d,J=6.7Hz,6H),0.89(d,J=6.8Hz,6H);13C NMR(101MHz,CDCl3)δ151.23,150.24,150.22,140.51,140.34,138.49,138.40,132.54,132.52,131.69,131.67,127.42,127.40,127.36,127.35,127.26,127.19,127.14,127.02,126.02,125.99,124.32,124.29,124.14,123.98,123.85,123.82,109.00,108.99,107.75,107.74,48.41,48.35,22.54,22.52,21.46.
本发明催化剂所应用的合成方法筛选如下所示的催化剂:
Figure BDA0003496408150000131
本发明的催化剂所应用的有机合成反应可以制备如下所示的轴手性含硫双芳基衍生物(Ar=2,6-diMe-4-OMe-C6H2):
Figure BDA0003496408150000141
以部分催化剂为例,合成轴手性含硫双芳基衍生物。
实施例11:化合物1的制备
将0.1mmol 2'-乙基-[1,1'-联苯]-2,6-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1j,以及0.01mmol 4-氯苯磺酸溶于1mL氘代氯仿在-60℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体1,收率为74%。
化合物1为:
Figure BDA0003496408150000142
1H NMR(400MHz,Chloroform-d)δ7.45–7.41(m,2H),7.38–7.30(m,2H),7.24–7.17(m,1H),6.85(d,J=8.6Hz,1H),6.69(s,2H),6.48(d,J=8.6Hz,1H),5.92(s,1H),4.64(s,1H),3.79(s,3H),2.45(m,8H),1.07(t,J=7.6Hz,3H);13C NMR(101MHz,Chloroform-d)δ159.76,153.04,152.05,145.11,144.38,131.41,130.87,129.83,129.77,129.68,127.15,123.36,114.69,114.27,113.04,108.48,55.31,26.45,22.47,15.12;HRMS(ESI)m/zcalcd.for C23H24NaO3S(M+Na)+:403.1338,found:403.1336;separation of enantiomersby HPLC,
Figure BDA0003496408150000143
Column IF,30℃,n-hexane:i-PrOH=90:10,1mL/min,minorretention time:6.63min,major retention time:7.16min,er=4:96;[α]D 20=-31.4(c=1.0,CHCl3).
实施例12:化合物2的制备
将0.1mmol 2',5'-二氯-[1,1'-联苯]-2,6-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1j,以及0.01mmol 4-氯苯磺酸溶于1mL氘代氯仿在-60℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体2,收率为71%。
化合物2为:
Figure BDA0003496408150000151
1H NMR(400MHz,Chloroform-d)δ7.55–7.45(m,1H),7.39–7.30(m,2H),6.97(d,J=8.6Hz,1H),6.68(s,2H),6.46(d,J=8.6Hz,1H),6.28(s,1H),4.78(s,1H),3.78(s,3H),2.46(s,6H);13C NMR(101MHz,Chloroform-d)δ159.78,153.27,152.84,144.14,133.83,133.23,133.14,132.79,132.56,131.28,130.14,123.51,114.37,113.19,112.39,109.03,55.32,22.54;HRMS(ESI)m/z calcd.for C21H18Cl2NaO3S(M+Na)+:443.0246,found:443.0244;separation of enantiomers by HPLC,
Figure BDA0003496408150000153
Column IC,30℃,n-hexane:i-PrOH=88:12,1mL/min,minor retention time:4.96min,major retention time:4.36min,er=5:95;[α]D 20=-10.2(c=1.0,CHCl3).
实施例13:化合物3的制备
将0.1mmol 2'-氯-5'-甲氧基-[1,1'-联苯]-2,6-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1j,以及0.01mmol 4-氯苯磺酸溶于1mL氘代氯仿在-60℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体3,收率为62%。
化合物3为:
Figure BDA0003496408150000152
1H NMR(400MHz,Methanol-d4)δ7.31–7.17(m,2H),7.09(td,J=8.5,2.6Hz,1H),6.74(s,2H),6.46(d,J=8.6Hz,1H),6.29(d,J=8.6Hz,1H),3.78(s,3H),2.41(s,6H);13CNMR(101MHz,Chloroform-d)δ162.67(d,J=251.4Hz),159.64,153.39,152.90,144.03,136.38(d,J=10.4Hz),133.69(d,J=8.8Hz),132.41,127.28(d,J=3.7Hz),123.44,117.70(d,J=24.6Hz),114.82(d,J=21.1Hz),114.23,112.95,112.29,108.79,55.19,22.39;19F NMR(376MHz,Methanol-d4)δ-115.75;HRMS(ESI)m/z calcd.for C21H18ClFNaO3S(M+Na)+:427.0541,found:427.0537;separation of enantiomers by HPLC,
Figure BDA0003496408150000161
Column IC,30℃,n-hexane:i-PrOH=95:5,1mL/min,minor retention time:8.55min,major retention time:7.47min,er=5:95;[α]D 20=-7.0(c=1.0,CHCl3).
实施例14:化合物4的制备
将0.1mmol 2',3'-二氯-[1,1'-联苯]-2,6-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1j,以及0.01mmol 4-氯苯磺酸溶于1mL氘代氯仿在-60℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体4,收率为75%。
化合物4为:
Figure BDA0003496408150000162
1H NMR(400MHz,Chloroform-d)δ7.55(dd,J=7.9,1.6Hz,1H),7.33(t,J=7.7Hz,1H),7.29–7.21(m,1H),6.98(d,J=8.7Hz,1H),6.68(s,2H),6.47(d,J=8.7Hz,1H),6.27(s,1H),4.72(s,1H),3.78(s,3H),2.46(s,6H);13C NMR(101MHz,Chloroform-d)δ159.77,153.22,152.79,144.13,134.25,133.99,133.77,132.66,130.94,130.78,127.93,123.56,114.37,109.01,55.32,22.53;HRMS(ESI)m/z calcd.for C21H18Cl2NaO3S(M+Na)+:443.0246,found:443.0246;separation of enantiomers by HPLC,
Figure BDA0003496408150000163
ColumnIF,30℃,n-hexane:i-PrOH=91:9,1mL/min,minor retention time:8.88min,majorretention time:9.73min,er=5.5:94.5;[α]D 20=-38.4(c=1.0,CHCl3).
实施例15:化合物5的制备
将0.1mmol 2'-甲氧基-6'-(甲氧基甲基)-[1,1'-联苯]-2,6-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1j,以及0.01mmol 4-氯苯磺酸溶于1mL氘代氯仿在-60℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体5,收率为61%。
化合物5为:
Figure BDA0003496408150000171
1H NMR(400MHz,Chloroform-d)δ7.20(d,J=8.4Hz,1H),7.14(d,J=2.7Hz,1H),6.99(dd,J=8.4,2.7Hz,1H),6.77(d,J=8.6Hz,1H),6.70(s,2H),6.48(d,J=8.6Hz,1H),6.08(s,1H),4.31–4.10(m,2H),3.87(s,3H),3.79(s,3H),3.31(s,3H),2.46(s,6H);13C NMR(101MHz,Chloroform-d)δ160.40,159.79,153.51,152.14,144.58,139.64,132.84,130.19,123.05,122.71,115.22,114.88,114.60,114.23,113.97,109.46,73.23,58.73,55.51,55.29,22.43;HRMS(ESI)m/z calcd.for C24H26NaO5S(M+Na)+:449.1393,found:449.1390;separation of enantiomers by HPLC,
Figure BDA0003496408150000172
Column IF,30℃,n-hexane:i-PrOH=88:12,1mL/min,minor retention time:12.82min,major retention time:14.89min,er=6.5:93.5;[α]D 20=-37.0(c=1.0,CHCl3).
实施例16:化合物6的制备
将0.1mmol 2-(5-溴代萘-1-基)苯-1,3-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1f,以及0.01mmol 4-氯苯磺酸溶于0.5mL氘代氯仿:氘代二氯甲烷(v:v=1:1),在-70℃下搅拌40小时。通过硅胶纯化粗混合物,得到白色固体6,收率为91%。
化合物6为:
Figure BDA0003496408150000173
1H NMR(400MHz,Chloroform-d)δ8.41(d,J=8.5Hz,1H),7.84(d,J=7.4Hz,1H),7.73(dd,J=8.6,7.0Hz,1H),7.60–7.50(m,2H),7.30(t,J=7.9Hz,1H),6.96(d,J=8.6Hz,1H),6.71(s,2H),6.55(d,J=8.7Hz,1H),5.98(s,1H),4.60(s,1H),3.80(s,3H),2.49(s,6H);13C NMR(101MHz,Chloroform-d)δ159.87,153.59,152.68,144.42,133.65,132.90,131.64,130.90,130.20,129.71,128.97,127.45,127.32,125.49,123.63,123.14,114.36,113.45,113.09,108.89,55.33,22.55;HRMS(ESI)m/z calcd.for C25H21BrNaO3S(M+Na)+:503.0287,found:503.0285;separation of enantiomers by HPLC,
Figure BDA0003496408150000181
ColumnIF,30℃,n-hexane:i-PrOH=88:12,1mL/min,minor retention time:8.88min,majorretention time:11.23min,er=8.5:91.5;[α]D 20=-131.3(c=0.3,CHCl3).
实施例17:化合物7的制备
将0.1mmol 2-(4-甲基萘-1-基)苯-1,3-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1h,以及0.01mmol 4-氯苯磺酸溶于0.5mL氘代氯仿:氘代二氯甲烷(v:v=1:1),在-70℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体7,收率为53%。
化合物7为:
Figure BDA0003496408150000182
1H NMR(400MHz,Chloroform-d)δ8.30–8.01(m,1H),7.59(m,2H),7.53–7.39(m,3H),6.88(d,J=8.6Hz,1H),6.72(s,2H),6.55(d,J=8.6Hz,1H),5.86(s,1H),4.70(s,1H),3.80(s,3H),2.78(s,1H),2.50(s,6H);13C NMR(101MHz,Chloroform-d)δ159.82,153.49,152.42,144.62,136.50,133.56,132.26,130.66,129.15,126.92,126.82,126.73,126.65,125.96,124.90,123.08,114.28,113.59,113.43,108.61,55.31,22.52,19.77;HRMS(ESI)m/z calcd.for C26H24NaO3S(M+Na)+:439.1338,found:439.1338;separation ofenantiomers by HPLC,
Figure BDA0003496408150000183
Column IF,30℃,n-hexane:i-PrOH=88:12,1mL/min,minor retention time:9.14min,major retention time:10.66min,er=3.5:96.5;[α]D 20=-91.2(c=1.0,CHCl3).
实施例18:化合物8的制备
将0.1mmol 2-(4-甲氧基萘-1-基)苯-1,3-二醇、0.15mmol 2,6-二甲基,4-甲氧基-硫芳基试剂和0.01mmol催化剂(R)-1f,以及0.01mmol 4-氯苯磺酸溶于0.5mL氘代氯仿:氘代二氯甲烷(v:v=1:1),在-70℃下搅拌24小时,然后升温至-20℃搅拌5小时。通过硅胶纯化粗混合物,得到白色固体8,收率为70%。
化合物8为:
Figure BDA0003496408150000191
1H NMR(400MHz,Chloroform-d)δ8.37(d,J=8.2Hz,1H),7.68–7.37(m,4H),6.95(d,J=7.9Hz,1H),6.85(d,J=8.6Hz,1H),6.72(s,2H),6.54(d,J=8.6Hz,1H),5.82(s,1H),4.73(s,1H),4.07(s,3H),3.80(s,3H),2.50(s,6H);13C NMR(101MHz,Chloroform-d)δ159.83,156.74,153.64,152.52,144.69,133.21,130.35,129.80,127.70,126.54,126.13,125.12,123.02,122.76,120.01,114.26,113.44,113.33,108.47,104.08,55.81,55.31,22.51;HRMS(ESI)m/z calcd.for C26H24NaO4S(M+Na)+:455.1288,found:455.1288;separation of enantiomers by HPLC,
Figure BDA0003496408150000192
Column IF,30℃,n-hexane:i-PrOH=88:12,1mL/min,minor retention time:12.81min,major retention time:15.88min,er=4:96;[α]D 20=-67.0(c=1.0,CHCl3).
上述的对实施例的描述是为便于该技术领域的普通技术人员能理解和使用发明。熟悉本领域技术的人员显然可以容易地对这些实施例做出各种修改,并把在此说明的一般原理应用到其他实施例中而不必经过创造性的劳动。因此,本发明不限于上述实施例,本领域技术人员根据本发明的揭示,不脱离本发明范畴所做出的改进和修改都应该在本发明的保护范围之内。

Claims (8)

1.一种手性联萘催化剂的应用,其特征在于,所述催化剂用于制备轴手性含硫双芳基衍生物,具体方法为:
室温下,将双芳基苯酚、硫芳基试剂、催化剂和酸加入反应管中,低温条件下,加入溶剂,于氩气氛围中反应一段时间后,将体系升至一定温度,继续反应一段时间,后经减压蒸馏、柱色谱提纯,制得轴手性含硫双芳基衍生物,该应用的合成路线为:
Figure FDA0004134643320000011
其中,R选自烷基、氧烷基或卤素取代基;
该催化剂为3,3′-二取代联萘衍生硒化物,为以下结构式之一:
Figure FDA0004134643320000012
2.根据权利要求1所述的一种手性联萘催化剂的应用,其特征在于,该催化剂制备方法为:将手性联萘酚与三氯化磷、三乙胺、二异丙胺,在硒粉以及溶剂的共同作用下,生成手性联萘催化剂。
3.根据权利要求2所述的一种手性联萘催化剂的应用,其特征在于,具体步骤为:将三氯化磷溶解于溶剂中,冷却至低温0℃后,并向其中加入三乙胺,反应后将体系升至室温,并添加二异丙胺,然后搅拌,在室温下向体系中加入手性联萘酚的衍生物搅拌反应,室温条件下加入硒,继续搅拌反应,后经减压蒸馏、柱色谱提纯,得到催化剂。
4.根据权利要求2或3所述的一种手性联萘催化剂的应用,其特征在于,所述溶剂为二氯甲烷。
5.根据权利要求3所述的一种手性联萘催化剂的应用,其特征在于,将三氯化磷溶解于二氯甲烷中,冷却至低温0℃后,并向其中逐滴滴加三乙胺,反应10min后将体系升至室温,并添加二异丙胺,然后搅拌2h,在室温下向体系中加入手性联萘酚的衍生物搅拌反应12h,室温条件下加入硒,继续搅拌反应2h。
6.根据权利要求1所述的一种手性联萘催化剂的应用,其特征在于,所述的酸为对氯苯磺酸,所述的溶剂包括氘氯或氘氯与氘代二氯甲烷中的一种。
7.根据权利要求1所述的一种手性联萘催化剂的应用,其特征在于,所述的双芳基苯酚与硫芳基试剂的摩尔比为1:1.0-1.8,所述催化剂与双芳基苯酚的摩尔比为0.05-0.12:1。
8.根据权利要求1所述的一种手性联萘催化剂的应用,其特征在于,所述的酸与双芳基苯酚的摩尔比为0.05-0.12:1,所述的低温反应的温度为-60℃,反应时间为20-28h,升温后的反应的温度为-20℃,反应时间为4-7h。
CN202210116253.XA 2022-02-07 2022-02-07 一种手性联萘催化剂及其制备方法和应用 Active CN114870892B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210116253.XA CN114870892B (zh) 2022-02-07 2022-02-07 一种手性联萘催化剂及其制备方法和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210116253.XA CN114870892B (zh) 2022-02-07 2022-02-07 一种手性联萘催化剂及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114870892A CN114870892A (zh) 2022-08-09
CN114870892B true CN114870892B (zh) 2023-04-28

Family

ID=82668229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210116253.XA Active CN114870892B (zh) 2022-02-07 2022-02-07 一种手性联萘催化剂及其制备方法和应用

Country Status (1)

Country Link
CN (1) CN114870892B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115155658B (zh) * 2022-09-06 2022-11-25 泽升科技(广州)有限公司 一类基于vapol合成硒硫类化合物的合成方法
CN115197271B (zh) * 2022-09-06 2022-12-09 泽升科技(广州)有限公司 一类基于1,2-二芳基-1,2-乙二醇(胺)的硒/硫类化合物及其合成方法
CN115490732B (zh) * 2022-09-30 2023-04-25 安徽泽升科技有限公司 一类手性联苯二醇类催化剂的合成方法
CN115572311B (zh) * 2022-09-30 2023-04-28 安徽泽升科技有限公司 一类基于联萘二硫醇合成硒/硫类化合物的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100364999C (zh) * 2006-03-03 2008-01-30 中国科学院长春应用化学研究所 手性联萘酚硅氧烷衍生物及其制备方法
CN111217809B (zh) * 2018-11-27 2021-06-08 江苏奥赛康药业有限公司 一类手性含氮双烯配体及其制备方法和应用
CN111116450B (zh) * 2019-12-16 2023-02-21 上海交通大学 一种轴手性萘胺方酰胺类有机催化剂及其制备方法和应用
CN111285901A (zh) * 2020-02-27 2020-06-16 上海交通大学 基于1,1`-联-2-萘酚骨架的手性硫/硒化合物及其制备方法和应用
CN111205328B (zh) * 2020-02-27 2021-07-13 上海交通大学 一种手性硫/硒化合物及其制备方法和应用

Also Published As

Publication number Publication date
CN114870892A (zh) 2022-08-09

Similar Documents

Publication Publication Date Title
CN114870892B (zh) 一种手性联萘催化剂及其制备方法和应用
CN114478337B (zh) 一种轴手性含硫双芳基衍生物及其合成方法
CN111285901A (zh) 基于1,1`-联-2-萘酚骨架的手性硫/硒化合物及其制备方法和应用
CN114524701B (zh) 一种n-n轴手性吡咯衍生物及其合成方法
Damjanović et al. The synthesis, structure and catalytic properties of the [Mo 7 O 24 (μ-Mo 8 O 26) Mo 7 O 24] 16− anion formed via two intermediate heptamolybdates [Co (en) 3] 2 [NaMo 7 O 24] Cl· n H 2 O and (H 3 O)[Co (en) 3] 2 [Mo 7 O 24] Cl· 9H 2 O
CN113856762A (zh) 高聚Salen钴催化剂和制备方法及应用
CN114456181A (zh) 一种芦可替尼的制备方法
Macedo et al. Enantioselective addition of diethylzinc to aldehydes catalyzed by pyridineoxazolinealcohols
Cullis et al. Synthesis of chiral [16 O, 17 O, 18 O] phosphate esters
US8691998B2 (en) Catalysts containing N-heterocyclic carbenes for enantioselective synthesis
CN112724171B (zh) 一种2-膦酰基-3-氟代乙烯基吲哚化合物及其制备方法
CN115010753A (zh) 一种水相中制备磷酸化偕二氟二烯烃化合物的方法
CN114478245A (zh) 一种手性γ-炔基-α-酮酸酯类化合物的不对称合成方法
CN115353529A (zh) 手性螺环化合物、其制备方法及其应用
CN111423351B (zh) 手性铜复合物及其制备方法和应用
Yang et al. Enantiopure encaged Verkade's superbases: Synthesis, chiroptical properties, and use as chiral derivatizing agent
EP4038075A1 (fr) Procede de preparation d'alcenylaminoboranes et de leurs derives, et leurs utilisations
CN115181129B (zh) 一类基于vanol合成手性硒硫类化合物的合成方法
Langenohl et al. A Silicon‐Stereogenic Silanol‐18O‐Isotope Labeling and Stereogenic Probe Reveals Hidden Stereospecific Water Exchange Reaction
CN115155658B (zh) 一类基于vapol合成硒硫类化合物的合成方法
JP2003146978A (ja) シス−β構造を有するサレンコバルト錯体を用いる光学活性なラクトン化合物の製造方法
CN114160206B (zh) 一种催化合成光学活性吲哚类化合物的催化剂、应用、合成方法及光学活性吲哚类化合物
CN115490732B (zh) 一类手性联苯二醇类催化剂的合成方法
CN117924343A (zh) 一种含硅手性中心的新骨架硅杂苯并六元杂环化合物及其制备方法与应用
CN113831205A (zh) 一种手性吡唑啉酮化合物的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant